Technology.

Our Strategy – High-Value, High-Barrier Drugs.

Leveraging our integrated formulation, IP, and regulatory expertise to accelerate the path to market for two product categories:
  • 505(b)(2) NDAs Optimizing proven drugs to deliver products with enhanced safety and efficacy profiles.
  • High-barrier ANDAs Developing complex, hard-to-replicate generics to provide patients with affordable therapeutics.

ONCORE™ Technology (Oral KI Optimization).

Conventional Kinase Inhibitors (KIs) often suffer from low and unpredictable GI absorption. ONCORE™ resolves these issues using a proprietary novel salt formulation:

Enhanced Bioavailability
Improves systemic absorption, allowing for lower therapeutic doses, reduced blood drug concentration fluctuation, and a potential reduction in adverse events (AEs).
1
Reduced pH & PPI Effects
Limits the impact of GI pH variations, meaning medications can be co-administered with acid-reducing agents (PPIs/antacids).
2
Improved Safety & Compliance
Reduces food-effect risks (such as QT interval prolongation) and allows medication to be taken with food, greatly improving patient compliance.
3

FlexDose® Technology (Advanced ODT).

FlexDose® delivers Orally Disintegrating Tablets (ODTs) engineered for underserved neurology patients.
Rapid Disintegration
Tablets dissolve instantly in the mouth and can be swallowed without water.
1
Designed for Dysphagia
Provides a critical, easy-to-use alternative for pediatric, geriatric, or severely ill patients with clinical swallowing difficulties or nausea.
2
Superior Patient Experience
Formulated with advanced taste-masking technology and significantly reduced mucosal irritation.
3

Pipeline.

Handa Pharma Oncology Pipeline

PHYRAGO™
OMCAZIO™
HND-044
HND-027
HND-054
HND-055

Handa Pharma Neurology Pipeline

TASCENSO ODT®
HND-045
HND-053

Handa Pharma ANDA Pipeline

Dexlansoprazole DR
Quetiapine XR

Resources.

Handa’s expertise includes patent analysis, analytical development, oral drug delivery technologies, quality-by-design principles, quality assurance, clinical trial monitoring, patent litigation, process development, commercial scale-up, supply chain management and regulatory affairs.

All Handa R&D team members have backgrounds in medicine, pharmaceuticals or chemistry (MSc or Ph.D.), and our average industry work experience is more than 10 years.

We operate two R&D sites

  • Tainan, Taiwan new R&D Center in Tainan Science Park Oral Solid MR and XR liquids center of excellence
  • Hangzhou, China R&D Center Oral Solid MR and FlexDose® (ODT and MR-ODT) center of excellence